Metastatic Breast Cancer
Conference Coverage
Cancer risk tied to some manufactured foods
The results of three European studies support the removal of trans fatty acids, nitrites, and nitrates from food products.
Conference Coverage
Breast cancer-related musculoskeletal pain alleviated with acupuncture
A new study shows that electroacupuncture and auricular acupuncture may relieve debilitating chronic musculoskeletal pain for breast cancer...
Conference Coverage
Sacituzumab govitecan effective in Black mTNBC patients
Black women may have outcomes comparable to those of other women when given sacituzumab govitecan for the treatment of metastatic TNBC, suggests...
Conference Coverage
PD-L1 cutoff for pembrolizumab in mTNBC confirmed
PD-L1 CPS of at least 10 improves overall survival by 28%-29%. Further analysis of responses to pembrolizumab plus chemotherapy in metastatic TNBC...
News
Pembrolizumab improves event-free survival in early TNBC
Neoadjuvant pembrolizumab benefits early TNBC patients regardless of disease stage and nodal status. Event-free survival improved by about 35%...
Conference Coverage
Antibiotic use associated with triple-negative breast cancer mortality
Antimicrobials can decrease circulating and tumor-infiltrating lymphocytes that effect the immune repertoire and in turn survival.
Conference Coverage
Omega-3 supplements may impact breast cancer risk
Two small studies suggest gut microbiota changes could influence susceptibility.
Conference Coverage
Women struggle with benzodiazepine addiction post chemotherapy treatment
Sedatives like benzodiazepines are used to control nausea, anxiety, and insomnia during chemotherapy treatment, but overuse and failing to taper...
Conference Coverage
‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancer
Two years of adjuvant palbociclib with endocrine therapy failed to improve invasive disease-free survival in patients with stage II-III HR-...
News
The evolving HER2+ metastatic breast cancer landscape: Novel agents and promising combination therapies
“The fact that we’re now talking about fourth- and fifth-line therapies for HER2-positive MBC represents a major advance in the management of...